Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Christopher W. Plummer"'
Autor:
Michele J Pachanski, Melissa E Kirkland, Daniel T Kosinski, Joel Mane, Boonlert Cheewatrakoolpong, Jiyan Xue, Daphne Szeto, Gail Forrest, Corin Miller, Michelle Bunzel, Christopher W Plummer, Harry R Chobanian, Michael W Miller, Sarah Souza, Brande S Thomas-Fowlkes, Aimie M Ogawa, Adam B Weinglass, Jerry Di Salvo, Xiaoyan Li, Yue Feng, Daniel A Tatosian, Andrew D Howard, Steven L Colletti, Maria E Trujillo
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0186033 (2017)
GPR40 agonists are effective antidiabetic agents believed to lower glucose through direct effects on the beta cell to increase glucose stimulated insulin secretion. However, not all GPR40 agonists are the same. Partial agonists lower glucose through
Externí odkaz:
https://doaj.org/article/32189b3be78e4819b3311bc01c779ade
Autor:
Judith N. Gorski, Maria E. Trujillo, Brande Thomas-Fowlkes, Adam B. Weinglass, Jerry Di Salvo, Aimie M. Ogawa, Sarah Souza, Christopher W. Plummer, Joel Mane, Michele Pachanski, Boonlert Cheewatrakoolpong, Andrew D. Howard, Steven L. Colletti
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 313:E37-E47
G protein-coupled receptor 40 (GPR40) partial agonists lower glucose through the potentiation of glucose-stimulated insulin secretion, which is believed to provide significant glucose lowering without the weight gain or hypoglycemic risk associated w
Autor:
Adam B Weinglass, Nicholas B Hastings, Bradley S Sherborne, Jennifer M. Johnston, Andrew D Howard, Maria Webb, Steven L. Colletti, Clemens Vonrhein, Kevin J. Lumb, Srivanya Tummala, Frank K Brown, Jennifer Hadix, Hubert Josien, Stephen M. Soisson, Guo Yan, Harry R. Chobanian, John Wang, Michael W. Miller, Brande Thomas-Fowlkes, Dawn L. Hall, Jeffrey D. Hermes, Thu Ho, Barbara Pio, Payal R. Sheth, Sujata Sharma, Maria Kornienko, Samantha J Allen, Sangita B. Patel, Jerry Di Salvo, Sarah Souza, Gérard Bricogne, Christopher W Plummer, Jun Lu, Noel Byrne
Publikováno v:
Nature Structural & Molecular Biology. 24:570-577
Clinical studies indicate that partial agonists of the G-protein-coupled, free fatty acid receptor 1 GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus. Full allosteric
Autor:
Melissa Kirkland, Randal M. Bugianesi, Melodie Christensen, Maria E. Trujillo, Michele Pachanski, Richard Tschirret-Guth, Josien Hubert B, Adam B. Weinglass, Sarah Souza, Ravi P. Nargund, Christopher W. Plummer, Andrew D. Howard, Joel Mane, Louis-Charles Campeau, Robert K. Orr, Daniel Kosinski, Xiaoping Zhang, Boonlert Cheewatrakoolpong, Jerry Di Salvo, Michael W. Miller, William K. Hagmann, Helen Chen, Steven L. Colletti, Andrew Nolting, Michael Wright, Matthew J. Clements, Murali Rajagopalan
Publikováno v:
ACS Medicinal Chemistry Letters. 8:221-226
GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secr
Autor:
Robert K. Orr, Harry R. Chobanian, Barbara Pio, Jamie M. McCabe Dunn, Louis-Charles Campeau, Rebecca T. Ruck, Andrew Nolting, Christopher W. Plummer
Publikováno v:
Synthesis. 49:657-666
A convergent three-step method for the synthesis of 2-substituted chromans is described. These results have been accomplished via the Heck coupling of readily accessible allylic alcohols and 2-iodophenols, followed by reduction and Mitsunobu cyclizat
Autor:
Peter E. Maligres, Melodie Christensen, Christopher W. Plummer, Andrew Nolting, Louis-Charles Campeau, Robert K. Orr, Rebecca T. Ruck, Michael Shevlin, Joshua Lee, Matthew T. Tudge, Mark Weisel
Publikováno v:
The Journal of Organic Chemistry. 81:824-830
α- and β-substitution of dihydrocinnamates has been shown to increase the biological activity of various drug candidates. Recently, we identified enantio- and diastereopure α-methyl-β-cyclopropyldihydrocinnamates to be important pharmacophores in
Autor:
Sarah Souza, Boonlert Cheewatrakoolpong, Christopher W. Plummer, Joel Mane, Steven L. Colletti, Jiyan Xue, Corin O. Miller, Yue Feng, Jerry Di Salvo, Gail Forrest, Harry R. Chobanian, Brande Thomas-Fowlkes, Daniel Kosinski, Daniel Tatosian, Daphne Szeto, Michele Pachanski, Melissa Kirkland, Andrew D. Howard, Xiaoyan Li, Adam B. Weinglass, Michelle Bunzel, Aimie M. Ogawa, Maria E. Trujillo, Michael W. Miller
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 10, p e0186033 (2017)
PLoS ONE, Vol 12, Iss 10, p e0186033 (2017)
GPR40 agonists are effective antidiabetic agents believed to lower glucose through direct effects on the beta cell to increase glucose stimulated insulin secretion. However, not all GPR40 agonists are the same. Partial agonists lower glucose through
Autor:
D. Euan MacIntyre, Yue Feng, Lauren P. Shearman, Xiao-Ming Guan, Mark T. Goulet, Christopher W. Plummer, Sharon Tong, Quang Truong, D. Sloan Stribling, Donald J. Marsh, Junying Wang, Hong Yu, Kimberly Rosko, Sander G. Mills, Paul E. Finke, Alison M. Strack, Stephanie K. Spann, L. H. T. Van Der Ploeg, Shrenik K. Shah, Douglas J. MacNeil, Ramon E. Camacho, Joseph M. Metzger, William K. Hagmann, Tung M. Fong
Publikováno v:
European Journal of Pharmacology. 579:215-224
We document in vitro and in vivo effects of a novel, selective cannabinoid CB 1 receptor inverse agonist, Imidazole 24b (5-(4-chlorophenyl)- N -cyclohexyl-4-(2,4-dichlorophenyl)-1-methyl-imidazole-2-carboxamide). The in vitro binding affinity of Imid
Autor:
Carolyn S. Wei, Christopher W. Plummer, Carrie E. Yozwiak, Sara O. Smithback, Arash Soheili, James L. Leighton
Publikováno v:
ChemInform. 46
Autor:
Sander G. Mills, Xinchun Tong, Christopher W. Plummer, Chun-Pyn Shen, Jing Chen, Paul E. Finke, D. Sloan Stribling, Lex H.T. Van der Ploeg, George A. Doss, Junying Wang, Alison M. Strack, Lauren P. Shearman, Tung M. Fong, Julie Z. Lao, Marie-Therese Schaeffer
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:1441-1446
Structure–activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CB1 receptor inverse agonists resulted in the discovery of the two amide derivatives 24a and b (hCB1 IC50 = 6.1 and 4.0 n